Publications

1.

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.

Feduccia, A.A., Jerome, L., Mithoefer, A., Yazar-Klosinski, B., Emerson, A., Doblin, R. (2019)

2.

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials

Mithoefer, M.C., Feduccia, A.A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Doblin, R. (2019)

3.

3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.

Ot’alora, G, M., Grigsby, J., Poulter, B., Van Derveer, J. W., Giron, S. G., Jerome, L., Feduccia, A., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M., Doblin, R. (2018)

4.

Reduction in Social Anxiety After MDMA-Assisted Psychotherapy with Autistic Adults: A Randomized, Double-blind, Placebo-Controlled Pilot Study.

Danforth, A.L., Grob, C.S., Struble, C., Feduccia, A.A., Walker, N., Jerome, L., Yazar-Klosinski, B., Emerson, A. (2018)

5.

3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy for Post-Traumatic Stress Disorder in Military Veterans, Firefighters, and Police Officers: A Randomised, Double-Blind, Dose-Response, Phase 2 Clinical Trial.

Mithoefer, M. C., Mithoefer, Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Doblin, R. (2018)

6.

Potential Psychiatric Uses for MDMA.

Yazar‐Klosinski, B., Mithoefer, M. (2017),

7.

MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.

Danforth A, Struble C, Yazar-Klosinski B, Grob C (2016)

8.

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study​.

Mithoefer M, Wagner M, Mithoefer A, Jerome L, Martin S, Yazar-Klosinski B, Michel Y, Brewerton T, Doblin R (2013)

9.

Can MDMA Play a Role in the Treatment of Substance Abuse?

Jerome L, Schuster S, Yazar-Klosinski B (2013

10.

The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Mithoefer M, Wagner M, Mithoefer A, Jerome L, Doblin R (2010

11.

The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.

Sumnall H, Cole J, Jerome L (2006)

12.

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Noller, G, Frampton, C, Yazar-Klosinski, B (2017)

13.

Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases

Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014)

14.

Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy

Feduccia, A. A., Jerome, L., Mithoefer, M. C., & Holland, J. (2020)

15.

The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD

Marseille, E., Kahn, J. G., Yazar-Klosinski, B., & Doblin, R. (2020).

16.

MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.

Wolfson, P. E., Andries, J., Feduccia, A. A., Jerome, L., Wang, J. B., Williams, E., … & Emerson, A. (2020).

17.

The past and future of psychedelic science: an introduction to this issue.

Doblin, R. E., Christiansen, M., Jerome, L., & Burge, B. (2019).

18.

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.

Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020). 

19.

The effects of stereotype threat on cognitive function in ecstasy users.

Cole, J. C., Michailidou, K., Jerome, L., & Sumnall, H. R. (2006). 

20.

MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial

Candice M. Monson, Anne C. Wagner, Ann T. Mithoefer, Rachel E. Liebman, Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin & Michael C. Mithoefer (2020)

MAPS Public Benefit Corporation

Our Mission
Who We Are
Careers
News
FAQ
Contact Us

3141 Stevens Creek Blvd #40547
San Jose, CA 95117

MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.